BoomRay Pharmaceuticals Overview
- Year Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$44.7M
- Investors
-
6
BoomRay Pharmaceuticals General Information
Description
Developer and clinical researcher of radionuclide targeted drugs designed for oncology. Having constructed a radionuclide drug development and transformation platform, the company focuses on accurate diagnosis and treatment of tumors, providing oncologist with advanced treatment solutions.
Contact Information
Website
www.boomray.comCorporate Office
- Building 7
- No. 19, Yong'an Road
- Suzhou, Jiangsu 215011
- China
Corporate Office
- Building 7
- No. 19, Yong'an Road
- Suzhou, Jiangsu 215011
- China
BoomRay Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 14-Jul-2022 | $44.7M | Completed | Generating Revenue | ||
| 1. Early Stage VC | 07-Jun-2022 | Completed | Generating Revenue |
BoomRay Pharmaceuticals Comparisons
Industry
Financing
Details
BoomRay Pharmaceuticals Competitors (15)
One of BoomRay Pharmaceuticals’s 15 competitors is Mabworks Biotech, a Venture Capital-Backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mabworks Biotech | Venture Capital-Backed | Beijing, China | ||||
| Helocyte | Venture Capital-Backed | New York, NY | ||||
| GMAX Bio | Venture Capital-Backed | Hangzhou, China | ||||
| Variant Bio | Venture Capital-Backed | Seattle, WA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
BoomRay Pharmaceuticals Patents
BoomRay Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026209056-A1 | Bicyclic peptide radionuclide ligand and chelate | Pending | 03-Apr-2025 | ||
| WO-2026114399-A1 | Bicyclic peptide radionuclide ligand and chelate | Pending | 29-Nov-2024 | ||
| WO-2026041108-A1 | Compound based on cyclic peptide and covalent warhead and use thereof | Pending | 23-Aug-2024 | ||
| WO-2026041109-A1 | Fibroblast activation protein inhibitor and use thereof | Pending | 23-Aug-2024 | ||
| WO-2026007871-A1 | Inhibitor targeting fibroblast activation protein | Pending | 01-Jul-2024 |
BoomRay Pharmaceuticals Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Chengdu Tianfu Sanjiang Asset Management | Venture Capital | Minority | ||
| HSG (Hong Kong) | Venture Capital | Minority | ||
| Puhua Capital | Venture Capital | Minority | ||
| Shenzhen Jinsheng Equity Investment Management | Growth/Expansion | Minority | ||
| Tsing Song Capital | Venture Capital | Minority |
BoomRay Pharmaceuticals FAQs
-
When was BoomRay Pharmaceuticals founded?
BoomRay Pharmaceuticals was founded in 2018.
-
Where is BoomRay Pharmaceuticals headquartered?
BoomRay Pharmaceuticals is headquartered in Suzhou, China.
-
What industry is BoomRay Pharmaceuticals in?
BoomRay Pharmaceuticals’s primary industry is Biotechnology.
-
Is BoomRay Pharmaceuticals a private or public company?
BoomRay Pharmaceuticals is a Private company.
-
What is BoomRay Pharmaceuticals’s current revenue?
The current revenue for BoomRay Pharmaceuticals is .
-
How much funding has BoomRay Pharmaceuticals raised over time?
BoomRay Pharmaceuticals has raised $52.2M.
-
Who are BoomRay Pharmaceuticals’s investors?
Chengdu Tianfu Sanjiang Asset Management, HSG (Hong Kong), Puhua Capital, Shenzhen Jinsheng Equity Investment Management, and Tsing Song Capital are 5 of 6 investors who have invested in BoomRay Pharmaceuticals.
-
Who are BoomRay Pharmaceuticals’s competitors?
Mabworks Biotech, Helocyte, GMAX Bio, Variant Bio, and CytomX Therapeutics are some of the 15 competitors of BoomRay Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process